Industry Strategies for NASH Combination Therapies

Introduction: Many have commented that drug combinations represent the future of NASH therapeutics. As indicated by Pfizer’s recent announcement, large pharma companies are putting efforts toward the...
Learn More

Is Rapid Reversal of Liver Fibrosis Possible?

Title: Is Rapid Reversal of Liver Fibrosis Possible? Author: Peter G. Traber Introduction Treatment of liver fibrosis is a major focus of drug development with multiple companies examining a variety...
Learn More

NASH Cirrhosis Space Poised to Heat Up

Title: NASH Cirrhosis Space Poised to Heat Up Author: Peter G. Traber, MD NASH cirrhosis is the most advanced classification of fibrosis progression in fatty liver disease. Results of clinical trials...
Learn More

Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...
Learn More

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...
Learn More

Identifying Best Disease Indications for Anti-Fibrotic Drugs

Identifying Best Disease Indications for Anti-Fibrotic Drugs By Peter G. Traber, MD
Learn More

mRNA vaccines: ready for prime time?

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Senolytics- taking aim at ageing cells

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Drugs and the human gut microbiome – beyond antibiotics

by Saadia Basharat, PhD, Consultant and Ashley Clark, Consultant Intern at Alacrita
Learn More

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita
Learn More

Why is it so daunting for US biotech and pharma to launch drugs in Europe themselves?

by Anna Casse, Managing Partner and Saadia Basharat, Consultant, at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita  
Learn More